Boeing Acquisition of Spirit AeroSystems Could Close Soon Amid Ongoing Conditions 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Netflix’s $72 Billion Warner Bros Discovery Deal Reshapes the Entertainment Landscape 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Lockheed Martin Secures $1.14 Billion Contract Boost for F-35 Production 
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
